Sponsors (7)
The bill would improve on-scene anaphylaxis response, public awareness, and transparency—potentially saving lives—but creates new federal costs and risks uneven implementation, privacy exposure, and limited campaign effectiveness without clearer funding, oversight, and coordination.
Law enforcement agencies (including officers in urban and rural communities) can obtain and carry emergency epinephrine, enabling faster on-scene treatment for anaphylaxis and potentially saving lives.
Parents, patients with chronic allergic conditions, first responders, and the general public will gain greater awareness of anaphylaxis symptoms and clarified responder roles, helping bystanders recognize emergencies and reducing delays to epinephrine administration.
Law enforcement agencies, local governments, researchers, and communities will get annual data on officer-administered epinephrine and public reporting, improving transparency and enabling better training, medical preparedness, and policy oversight.
Taxpayers and federal budgets will face new costs—grants to outfit officers and the administrative burden of collecting and publishing data—potentially increasing federal spending without specified offsets.
Law enforcement agencies and local governments may implement the program inconsistently and face risks of improper storage/use of epinephrine or legal liability because eligibility, training, and oversight details are unspecified.
The intended public-awareness campaign lacks dedicated funding, imposes a single 180-day deadline without enforcement, and assigns federal agencies design/implementation without explicit state/local coordination—making outreach likely uneven, delayed, or superficial, especially in rural areas.
Based on analysis of 4 sections of legislative text.
Introduced June 17, 2025 by Laura Gillen · Last progress June 17, 2025
Creates a federal grant program to improve law enforcement access to emergency epinephrine, requires the Department of Justice to publish annual data on how often law enforcement officers administer epinephrine products, and directs DOJ and HHS to run a public awareness campaign about anaphylaxis and the role of first responders in using epinephrine. The bill sets a 180‑day deadline for launching the awareness campaign but does not include funding amounts, detailed grant rules, or enforcement provisions in the provided text.